Approval · Notice of Compliance 18027 · 2016
NESINA: Notice of Compliance 18027
Issued April 6, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18027
- Date
- April 6, 2016
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph with the final 2 year data from the endure study, designed to assess the durability of efficacy and saety of aloglipin in combination with metformin compared with glipizide in combination with metformin in audlts with type 2 diabetes mellitus
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NESINA | Not yet assigned | — |
Medicinal ingredients
- ALOGLIPTIN BENZOATE 6.25 MG per TAB
- ALOGLIPTIN BENZOATE 12.5 MG per TAB
- ALOGLIPTIN BENZOATE 25 MG per TAB